Bookmark and Share

Rossana  Trotta

Rossana Trotta Ph.D.

Academic Title: Assistant Professor
Primary Appointment: Microbiology and Immunology
Location: BRB 8-043
Phone: 410-706-2190
Lab: 410-706-4476

Personal History:

  • 1990: M.S. Biology, University of Rome "La Sapienza", Italy
  • 1995: Ph.D. Medical Biotechnology, University of L’Aquila, Italy
  • 1996-2003: Post-doctoral Researcher, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
  • 2003-2013: Research Scientist, Div. of Human Genetics, Dept Molecular Virology, Immunology and Medical Genetics, and Comprehensive Cancer Center, The Ohio State University, Columbus, OH
  • 2013-present: Assistant Professor, Dept of Microbiology & Immunology and Marlene and Stewart Greenbaum Cancer Center, University of Maryland School of Medicine, Baltimore MD

Research Interests:

Dr. Trotta is a member of the Tumor and Immunotherapy Program within the University of Maryland Marlene and Stewart Greenebaum Cancer Center. One specific area of interest is Natural Killer (NK) Cell Biology. Her focus is to assess the molecular mechanisms regulating NK immune-regulatory and anti-tumor functions against myeloid leukemias. She has identified several key molecules (e.g MAPKs, SHIP1 and I2PP2A/SET, MiR-155) that positively or negatively influence NK cell activation induced by binding to tumor cells or CD16 triggering and by exposure to cytokines. The final goal of these and future studies is to further understand the role played by NK cells in the tumor microenvironment in order to find alternative ways to enhance NK anti-tumor activity.

A second area of research interest is to understanding the molecular mechanisms regulating chronic myelogenous leukemia (CML) disease progression. Indeed she has been working to determine the role played by tumor suppressors (e.g. P53 and Phosphatases) in survival of leukemic blasts. As a Research Assistant Professor working in Prof. Perrotti’s laboratory, her research focuses on understanding the role played by microRNAs in the interplay between NK cells, bone marrow microenvironment and leukemic stem/progenitor cells.


Selected Publications (from a total of 45 peer-reviewed journal articles)

  1. Briercheck E.L., Trotta R., Chen L., Hartlage A.S., Cole J.P., Cole T.D., Mao C., Banerjee P.P., Hsu H.T., Mace E.,M., Ciarlariello D., Mundy-Bosse B.L., Garcia-Cao I., Scoville S.D., Yu L., Pilarski R., Carson W.E., Leone G., Pandolfi P.P., Yu J., Orange J.S., Caligiuri M.A. PTEN is a Negative Regulator of NK Cell Cytolytic Function.  J. Immunol.  194: 1832-40, 2015.
  2. Hughes T., Briercheck E.L., Freud A.G., Trotta R., McClory S., Scoville K.K,, Deng Y., Cole J., Harrison N., Mao C., Zhang J., Benson D.M., Yu J., Caligiuri M.A. The Transcriptional Factor AHR Prevents the Differentiation of a Stage 3 Innate Lymphoid Cell Subset to Natural Killer Cells. Cancer Rep. 8:150-62, 2014.
  3. Park I.K., Trotta R., Yu J., and Caligiuri M.A. Axl /Gas6 pathway positively regulates FLT3 activation in human natural killer cell development. Eur. J. Immunol. 243:2750-5, 2013.
  4. Trotta R., Chen L., Costinean S., Josyula S., Mundy-Bosse B.L., Ciarlariello D., Mao C., Briercheck E.L., McConnel K, Mishra A., Yu L., Croce C.M, Caligiuri M.A. Overexpression of MiR-155 results in expansion, block in terminal differentiation  and functional activation of NK Cells. Blood, 121:3126-34,2013.
  5. Trotta R., Chen L., Ciarlariello D., Josyula S., Mao C., Costinean S., Yu L., Butchar J.P., Tridandapani S., Croce C.M, Caligiuri M.A. MiR-155 regulates IFN-g production in Natural Killer Cells. Blood. 119:3478-85, 2012.
  6. Trotta R., Ciarlariello D., Dal Col J.,  Mao H., Chen L., Briercheck E., Zhang J., Yu J., Perrotti D., Caligiuri M.A.  The PP2A inhibitor SET regulates Granzyme B expression in human natural killer cells. Blood. 117:2378-84,2011.
  7. Trotta R. , Dal Col J.,  Yu J, Ciarlariello D.,  Thomas B., Zhang X., Allard J. II, Wei M., Mao H., Byrd JC., Perrotti D., and Caligiuri MA. TGF-Utilizes SMAD3 to Inhibit CD16-mediated IFN-g Production and Antibody-Dependent Cellular Cytotoxicity in Human Natural Killer cells.  J. Immunol. 181:3784-92, 2008.
  8. Chang JS., Santhanam R., Trotta R., Neviani P., Eiring A., Briercheck E., Ronchetti M., Roy DC., Calabretta B., Caligiuri MA and D. Perrotti.  High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP E2-dependent suppression of C/EBPa-driven Myeloid Differentiation. Blood. 110:994-1003, 2007.
  9. Neviani P., Santhanam R., Oaks J., Eiring A., Notari M., Blaser BW., Liu S., Trotta R., Muthusamy N., Gambacorti-Passerini C., Druker BJ., Cortes J., Marcucci G., Chen CS, Verrills NM, Roy DC., Caligiuri MA., Bloomfield CD.,  Byrd J and D. Perrotti. FTY720, a new and alternative strategy for treating blast crisis CML and Ph1 ALL. J. Clin. Invest.  117:2408-21, 2007.
  10. Trotta R., Ciarlariello D., Dal Col J., Allard II J., Neviani P., Santhanam R., Mao H., Becknell B., Yu J., Ferketich AK., Thomas B., Modi A., Blaser BW.,  Perrotti  D., and Caligiuri MA. The PP2A Inhibitor SET Regulates Natural Killer Cell IFN-g Production. J. Exp. Med. 204:2397-405, 2007.
  11. Trotta R, Parihar R, Yu J, Becknell B, Allard II J, Wen J, Ding W, Mao H, Tridandapani S, Carson WE,  and Caligiuri MA. Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine co-stimulation. Blood. 105: 3011-3018. 2005.
  12. Becknell B., Trotta R, Yu J, Ding W, Mao HC, Hughes T, Marburger T, and Caligiuri MA. Efficient infection of human Natural Killer cells with an EBV/retroviral hybrid vector. J. Immunol. Methods. 296:115-123, 2005.
  13. Neviani, P., Santhanam R., Trotta R., Notari M., Blaser BW., Liu S., Mao H., Chang JS., Galietta A.,Uttam A., Roy DC., Valtieri M., Bruner-Klinovic R., Caligiuri MA., Bloomfield CD., Marcucci G., and Perrotti D. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.  Cancer Cell. 8:355-68, 2005.
  14. Trotta, R., T. Vignudelli, O. Candini, R. V. Intine, L. Pecorari, C. Guerzoni, G. Santilli, M.W. Byrom, S. Goldoni, L.P. Ford, M. A. Caligiuri, R.J. Maraia, D. Perrotti, and B. Calabretta. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell. 2:145-160,2003.
  15. Perrotti, D., V. Cesi, R. Trotta, C. Guerzoni, G. Santilli, K. Campbell, A. Iervolino, F. Condorelli, C. Gambacorti-Passerini, M.A. Caligiuri, and Bruno Calabretta. BCR/ABL suppresses C/EBPa expression through inhibitory action of hnRNP E2. Nat. Genet. 30: 48-58, 2002.
  16. Trotta, R., K. Fettucciari, L. Azzoni, B Abebe,  KA Puorro, LC Eisenlohr and B. Perussia.  Differential role of p38 and c-Jun N-Terminal Kinase 1 mitogen-activated protein kinases in NK cell cytotoxicity. J Immunol. 165 (12): 1782-1789, 2000
  17. Trotta, R., KA Puorro, M. Paroli , L.Azzoni,  B Abebe, LC Eisenlohr. and B. Perussia. Dependence of both spontaneous and antibody-dependent, granule exocytosis-mediated NK cell cytotoxicity on extracellular signal-regulated kinases. J Immunol. 161 (12):6648-56, 1998.
  18. Trotta, R., P. Kanakaraj and B. Perussia. FcgR-dependent Mitogen-Activated Protein Kinase activation in leukocytes: a common signal transduction event necessary for expression of TNF- and early activation genes. J. Exp.Med. 184:1027, 1996.